ARROWHEAD PHARMACEUTICALS INC Acción · US04280A1007 · ARWR · A2AGYB (XNAS) — cotizaciones en tiempo real, datos de la empresa, dividendos, fundamentales y análisis de cartera con IA en MoneyPeak

Resumen

Análisis impulsado por IA

Análisis fundamental

Descubre lo que realmente dicen los números — antes que el mercado

Analizar ahora

Sentimiento de noticias

¿Las noticias de hoy son una señal de compra o una alerta?

Analizar ahora

Comprar / Mantener / Vender

¿Comprar, mantener o vender? Obtén el veredicto de la IA ahora.

Analizar ahora

Evaluación de riesgos

Descubre riesgos ocultos antes de que afecten a tu cartera.

Analizar ahora

Valor justo

¿Esta acción está barata, correctamente valorada o sobrevalorada?

Analizar ahora

Últimos análisis de IA sobre ARROWHEAD PHARMACEUTICALS INC

Resumen de la Calificación de Analistas

Comprar

Compra Fuerte

Comprar

Mantener

Vender

Venta Fuerte

Sin cotización

01.05.2026 20:00

Cotizaciones actuales de ARROWHEAD PHARMACEUTICALS INC

Bolsa	Ticker	Moneda	Última operación	Precio	Variación diaria
NASDAQ	ARWR	USD	01.05.2026 20:00	74,81 USD	1,33 USD +1,81 %
IEX	ARWR	USD	01.05.2026 19:59	74,79 USD	1,31 USD +1,78 %
London	0HI3.L	USD	01.05.2026 15:14	74,93 USD	1,45 USD +1,97 %
Düsseldorf	APIRSD07.DUSB	EUR	30.04.2026 14:00	59,70 EUR	-1,58 EUR -2,58 %
Hamburg	APIRSD07.HAMB	EUR	30.04.2026 06:07	60,14 EUR	-
Quotrix	APIRSD07.DUSD	EUR	30.04.2026 05:27	60,12 EUR	-

Calificación de Riesgo ESG

B Bueno

Flotación y Liquidez de las Acciones

Flotación Libre 87,15 %

Acciones en Flotación 122,04 M

Acciones en Circulación 140,03 M

Fondos invertidos

Los siguientes fondos han invertido en ARROWHEAD PHARMACEUTICALS INC:

Fondo iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	Vol. en millones 238,06	Porcentaje (%) 0,56 %

Perfil de la empresa para ARROWHEAD PHARMACEUTICALS INC Acción

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.